← back to search

Koshi Mimori

Molecular Oncology (United States) · JP
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Cells and Metastasis, MicroRNA in disease regulation, Cancer Genomics and Diagnostics, and Cancer-related molecular mechanisms research.
h-index
85
citations
26,222
works
805
NIH funding
primary concept
Medicine
email

Recent publications

<i>MiR-155</i> -driven loss of ICOSL and SOCS1 in EBV+ gastric cancers renders abundant cytotoxic T cells ineffective, enabling immune evasion
Proceedings of the National Academy of Sciences 2026cited by 1position: contributordoi
Novel driver gene FIRRM regulates the cell cycle for promoting tumor growth in hepatocellular carcinoma.
2026cited by 0position: contributordoi
GDF15 promotes 5-Fluorouracil and Oxaliplatin resistance by promoting stem cell-like phenotype in colorectal cancer.
2026cited by 0position: contributordoi
Visionary Leadership in Cancer Care: An Interview With Professor Timothy J. Eberlein.
2026cited by 0position: contributordoi
PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin-Proteasome Pathway Dysregulation.
2026cited by 0position: contributordoi
TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair.
2026cited by 0position: contributordoi
Intratumoral &lt;i&gt;Fusobacterium nucleatum&lt;/i&gt; Drives Cancer-Associated Fibroblasts Enrichment and Immune Exclusion in Esophageal Squamous Cell Carcinoma.
2026cited by 0position: contributordoi
ZNF282 Promotes Colorectal Cancer Progression Possibly via E2F1 Activation.
2026cited by 0position: contributordoi
Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma.
2026cited by 0position: contributordoi
Table S3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Table S2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Data from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Table S1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure 2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure 4 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Table S1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S4 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S5 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Table S3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S4 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure 3 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure 1 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Figure S5 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Table S2 from Aberrant Hippo-YAP/TEAD Signaling Drives Malignant Transcriptional Reprogramming in External Auditory Canal Squamous Cell Carcinoma
2026cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 111 papers (2019–2026)Kuniaki Sato · La Jolla Alcohol Research32 papers (2019–2026)Takaaki Masuda · Niigata University Medical and Dental Hospital32 papers (2020–2026)Muneyuki Masuda · Kyushu University25 papers (2020–2026)Takashi Nakagawa · Tokai University24 papers (2020–2026)Noritaka Komune · Kyushu University24 papers (2020–2026)Takafumi Nakano · Fukuoka University Hospital24 papers (2020–2026)J. Silvio Gutkind · University of San Diego23 papers (2025–2026)Kenichi Taguchi · National Hospital Organization Kyushu Cancer Center23 papers (2025–2026)Takahiro Hongo · Kyushu University23 papers (2025–2026)Yoshihiro Kakeji · Ehime University22 papers (2019–2023)Kensuke Koike · 22 papers (2026–2026)Mayumi Ono · 22 papers (2026–2026)Shinsaku Itoyama · 22 papers (2026–2026) · 21 papers (2019–2023)Yohei Shimono · MDPI21 papers (2019–2023)Xin Qian · Nanjing University of Chinese Medicine21 papers (2019–2023) · 21 papers (2019–2023)Akira Yokoyama · University of Tokyo Health Sciences20 papers (2019–2023)Hidenari Hirata · National Cancer Center Hospital East20 papers (2021–2023)